Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.77 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.77 |
| ▸ | BCL6 | P41182 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | BCR | P11274 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183069 | 0.89 | KCNN3 (0.80) | KCNN3KCNN2BCL6POLBTP53 | |
| SCHEMBL183176 | 0.87 | KCNN3 (1.00) | KCNN3KCNN2BCL6POLBTP53 | |
| SCHEMBL30421528 | 0.87 | KCNN3 (1.00) | KCNN3KCNN2BCL6POLBTP53 | |
| SCHEMBL183151 | 0.86 | KCNN3 (0.82) | KCNN3KCNN2BCL6POLBTP53 | |
| SCHEMBL183385 | 0.85 | KCNN3 (0.80) | KCNN3KCNN2BCL6POLBTP53 | |
| SCHEMBL182996 | 0.84 | KCNN3 (0.80) | KCNN3KCNN2BCL6POLBTP53 | |
| SCHEMBL2850075 | 0.84 | KCNN3 (0.79) | KCNN3KCNN2BCL6ABL1BCR | |
| SCHEMBL183344 | 0.84 | KCNN3 (0.76) | KCNN3KCNN2BCL6POLBTP53 | |
| SCHEMBL183629 | 0.84 | KCNN3 (0.78) | KCNN3KCNN2BCL6POLBTP53 | |
| SCHEMBL183257 | 0.82 | KCNN3 (0.76) | KCNN3KCNN2BCL6POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | claimed |
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| WO-2008116912-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KCNN3 15/4885KCNN2 5/4885BCL6 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.